Caspofungin Intravenous (IV) Powder

Caspofungin Intravenous (IV) Powder

Form: Intravenous (IV) Powder

Strength: 50 mg/vial, 70 mg/vial

Reference Brands: Cancidas (US & EU)

Category: Anti-fungal

Caspofungin IV powder is approved in the EU and US for treating invasive fungal infections. In the EU, Merck’s Cancidas is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on comprehensive clinical data, biosimilarity assessments, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz. We facilitate efficient market access for caspofungin IV formulations, ensuring adherence to European and American standards for safe, effective antifungal therapy.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Nystatin Oral Suspensions/Tablets

Strength: Tab: 500,000 units, 1,000,000 units; Sus: 100,000 units/mL, 500,000 units/5 mL

Form: Tablets/Suspensions

Reference Brands: Mycostatin, Nilstat, Nystop(US)

View Details Get Enquiry
Nystatin Topical Creams and Ointments

Strength: 100,000 units/g, 100,000–300,000 units/g

Form: Topical Creams and Ointments

Reference Brands: Mycostatin, Nilstat, Nystop(US)

View Details Get Enquiry
Micafungin Intravenous (IV) Powder

Strength: 50 mg, 100 mg/vial

Form: Intravenous (IV) Powder

Reference Brands: Mycamine(US & EU)

View Details Get Enquiry
Anidulafungin injection

Strength: 50 mg/vial

Form: Intravenous (IV) Powder

Reference Brands: Eraxis(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.